Stryker has announced the global launch of the new Trevo XP ProVue Retriever. According to a company release, the Trevo XP ProVue Retriever expands the ProVue Retriever line with additional size and shape options for physicians. The Trevo ProVue Retrievers are the world’s first stent retrievers with full-length visibility and are built on Trevo technology which has delivered strong clinical results and positive patient outcomes for acute ischaemic stroke patients.
“The Trevo XP ProVue Retriever provides some of the best performance of the devices I’ve used over the years to treat acute ischaemic stroke. The unique full-length visibility provides key information that we can use to successfully remove clots more efficiently. When combined with the Merci Balloon Guide Catheter, I feel I have a system that is easy to use and provides the potential for consistently good results,” says Ronald Budzik, Interventional Neuroradiology/Neurointerventional Surgery; chair, Neuroscience Clinical Operations Council; co-director, Riverside Comprehensive Stroke Centre, Ohio Health, Riverside Methodist Hospital, Columbus, Ohio, USA.
Joey D English, director of Neurointerventional Services, California Pacific Medical Centre, San Francisco, California, USA, adds, “The new Trevo XP ProVue Retriever is smooth and easy to use. It has excellent deliverability and the visibility it provides allows me to confidently deploy the device in the best position to capture and remove the clot. I can visualise the clot and strut interaction during the case and this provides valuable feedback for clot removal.”
The Trevo XP ProVue Retriever is supported by robust clinical evidence from the TREVO and TREVO 2 clinical trials, which demonstrated high revascularisation and a high rate of good clinical outcomes compared to the earlier generation Merci Retriever. Additionally, physicians participating in the Trevo Retriever Registry, a multicentre, international data collection study, will be collecting real world data on the Trevo XP ProVue Retriever. The device has been granted 510(k) market clearance by the U.S. Food and Drug Administration and is also available in international markets where it has been cleared for sale.